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In a criticism of our short report characterizing the
immunogenicity of hylan G-F 20 in rabbits, Burns et al.
make a number of points that are misinformed and fail to
view our ﬁndings within the framework of the many related
preclinical and clinical reports in the literature. The authors
attempt to discredit our conclusions that an immunogenic
component in hylan may underlie severe acute inﬂamma-
tory reactions (SAIRs) by pointing out that all hyaluronate-
based preparations have residual non-human protein levels
that could be immunogenic in humans. However, immuno-
genicity relates as importantly to quality as to the quantity of
the potential immunogen. The authors seem to be unaware
of our previously published study in which we describe the
details of the immunogenicity testing in rabbits and the
source of the pooled sera for the present study1. Clearly,
there are residual proteins in all hyaluronan preparations,
including hylan, but experimental attempts in four separate
studies have only demonstrated a response to hylan1e4.
Our working hypothesis, developed to attempt to explain
this empirical observation, is that the chemical crosslinking
of hylan during its manufacture, a process known to
enhance immunogenicity of proteins in general, may
qualitatively change the nature of residual contaminants,
rendering them immunogenic. Our present short communi-
cation adds credence to this assumption and even identiﬁes
a unique band that is recognized only by pooled sera from
hylan G-F 20-immunized rabbits.
The authors further state that sodium hyaluronate
contains the warning on its label that anaphylactoid and
allergic reactions have been reported, which is a warning not
contained on the hylan label, and cite this as proof that
sodium hyaluronate can be immunogenic. Basic principles of
pharmaco-vigilance state that postmarketing information
included in product labels, based on spontaneous anecdotal
reports ﬁled by health professionals or patients regarding
products that differ in their global distribution and duration of
time in the respective markets, cannot be used to scientif-
ically determine a frequency of an event, or to compare
products with respect to the occurrence of a given event.
Furthermore, we remind the authors that the hylan G-F 20
label does contain contraindication language that states ‘‘Do
not administer to patients with known hypersensitivity
(allergy) to hyaluronan (sodium hyaluronate) preparations’’5.
Additional patient information in the hylan G-F 20 labeling
implies that prior sensitization or exposure is associated with
a higher frequency of reactions: ‘‘The occurrence of post-
injection effusion may be associated with patient history of
effusion, advanced stage of disease and/or the number of
injections or treatment courses a patient receives.’’ With
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published reports and their temporal relationship to product
usage. There have been over 150 million injections of the
naturally extracted sodium hyaluronate products adminis-
tered since 1987 without a single published report of SAIRs
being associated with any of those products approved in the
US. Within the same timeframe, the numerous reports of
SAIRs in the clinical literature, which provide sufﬁcient
information to identify the distinct clinical nature of these
reactions, have related only to hylan5,6.
The authors incorrectly state that a ‘‘more thorough’’
reading of the article by Puttick et al.6 indicates that while one
patient had chicken-reactive antibodies following treatment
with hylan, this patient did not have antibodies to hylan. In
that report, the authors actually stated that this patient ‘‘had
signiﬁcant antibody titers to hylan and to chicken serum
proteins.Serum antibodies to intact hyaluronan were not
found.’’ This ﬁnding, while obviously uncontrolled, was
certainly suggestive and helped form the groundwork for
our corroborating investigations as well as others.
Burns et al. criticized our experimental methods, stating
that it would be useful for interpretation to understand
whether these were the same immunized animals as in our
previous study. Yet in our report, we clearly stated that
Western blots were performed ‘‘using the rabbit antisera
from rabbits immunized with various sources of hyalur-
onans as previously described’’; in other words, sera from
the same animals were used. Pooling of antisera for
biochemical evaluations is not uncommon, and we think
that in showing enzyme linked immunosorbent assay
(ELISA) results from both individual rabbits and our sera
pool, we have accomplished our aim to demonstrate that
the pooled sera used for the Western analysis exhibited the
same performance in the ELISA that we described in our
previous publication1. Finally, we fail to understand how
identiﬁcation of the migration of hyaluronidase or other
contaminants in the gel system would change the in-
terpretation of our results, as these remained the same
across blots developed with Crude Rooster Comb (CRC)-,
hylan-, and sodium hyaluronate-speciﬁc sera. In addition,
the authors state that the faint reactivity of the 6e8 kDa
band compared with the strong reactivity of the CRC
antisera does not appear to correlate with the ELISA
reactivity. We ﬁnd this observation to be irrelevant, as there
are many immunogenic species present in the CRC
preparation that are not present in the ﬁnished hyaluronate
products which likely contributed to the CRC-speciﬁc
immune response; it is unlikely the band seen in this region
on the CRC blot represents only our species of interest. In
response to the authors’ assertion that a demonstration of
hylan antisera reactivity with a hylan Western blot would be
more convincing, we point out that the amount of starting
hylan product per gel lane necessary to detect a single
species on Western blot imposes technical limitations. We
believe that puriﬁcation of this component from hylan will be0
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and, because the cost of hylan G-F 20 is prohibitive, we
would encourage the company to conduct such studies as
a commitment to further explore this safety concern.
The authors state that it is not credible to imply that no
immunogenic potential exists for an implantable material.
We never made nor intended to make such a statement.
We stated only that a difference in immunogenicity may
underlie the SAIRs that have been documented in the
literature. It is important to interpret our ﬁndings within the
framework of building published evidence from numerous
laboratories on this topic. There are now 16 published
reports of SAIRs to hylan, reviewed in Hamburger et al.7
and Goldberg and Coutts8 or described in four newer
reports9e12; none have associated these reactions with
sodium hyaluronate. There have also been four clinical
reports regarding chronic granulomatous reactions follow-
ing hylan G-F 20 injections, the most recent of which was
initially diagnosed as a sarcoma, and subsequently termed
a ‘pseudosarcoma’13. The preclinical data leading to similar
conclusions to those we have made are particularly
compelling: these reports have demonstrated that hylan
can elicit antibody responses, passive cutaneous anaphy-
laxis, inﬂammatory inﬁltrates after repeat exposure, and
granulomatous reactions in guinea pigs, mice and rab-
bitsdwhereas two comparator, naturally derived sodium
hyaluronates elicited no discernible reaction1e4. Our recent
work was a logical extension to further characterize the
possible cause of this response. We acknowledge the
preliminary nature of the work, but think that there are
sufﬁcient data indicating a difference in how these two
products are recognized by animals.
Further work, now ongoing, is necessary to identify and
further characterize this species and to evaluate if such
a target plays a role in the reactions seen in patients. We ﬁnd
it disturbing that the authors’ response as representatives of
the company that manufactures and distributes hylan G-F 20
was entirely antagonistic, and ignored the body of clinical
and preclinical literature documenting the occurrence of
these reactions to hylanG-F 20. In light of the present climate
regarding patient safety as it pertains to the current oral
therapies utilized for chronic pain management of OA, we
hoped such observations would have been embraced by the
company, and a commitment made to follow-up on ﬁndings
that represent a legitimate safety concern. In this way, all of
us can best serve the safety and needs of our patients.
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